Den kom før deadline i fjor men etter deadline året før.
Extension of preclinical research collaboration agreement with a top-10 large pharma company
Oslo (Norway), 10 July 2017 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company today announced that they are extending the preclinical research collaboration with an undisclosed top-10 pharma company, initiated in September 2015. The extended evaluation period spans over six months, until the end of 2017, and may be further extended.